Frovatriptan as Preemptive Treatment for Fasting-Induced Migraine
Meryl Latsko, MD, MPH; Stephen D. Silberstein, MD
Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA

OBJECTIVE:

Demographic and Headache Characteristics of the
Two Treatment Groups

Development of Headache of Moderate or Severe Intensity

To examine frovatriptan’s efficacy as preemptive treatment for fastinginduced migraine.

BACKGROUND:
Fasting is a common trigger of migraine. Since it cannot always be avoided,
the development of a short-term preemptive approach would benefit
migraineurs. Frovatriptan, because of its longer half-life, has been effectively
used for short-term daily use to prevent menstrually related migraines, and
might prove useful in the prevention of fasting-induced migraine.

METHODS:
I Double-blind, placebo-controlled, randomized, parallel-group trial.

Development of Headache at 6 to 20 Hours After Onset of Fast

I Subjects with a history of fasting-induced episodic migraine were

randomly assigned to receive either frovatriptan 5.0 mg. or placebo
(ratio 1:1).
I Subjects took a single dose of study medication at the start of their

CONCLUSION:

20-hour fast.
I Headache development, severity, and rescue use were captured at

defined time points from the start of the fast through 20 hours after
the start of the fast.

RESULTS:
I 75 subjects screened; 74 randomized.
I All subjects who took study drug were included in safety analyses

p=0.172 NS
*Subject developed headache of moderate to severe intensity, or developed a mild headache after a minimum
of 6 hours that became moderate or severe within 20 hours.

I More subjects on placebo developed a headache than did those on

frovatriptan.
I Our pilot study did not achieve statistical significance, perhaps because

Time to Development of Headache of Any Intensity

of the small number of subjects.
I Because of frovatriptan’s effectiveness as a short-term preventive for

menstrual migraine, a larger study to address the effectiveness of
frovatriptan for the prevention of fasting-induced migraine may be
warranted.

(N=71).
I 67 subjects included in efficacy analyses.
I There was no statistical difference between the 2 treatment groups with

respect to the development of a headache (Pearson Chi-Square, p=0.172).
I Kaplan-Meier (KM) survival analysis showed no difference between the

2 treatment groups with respect to the time of onset of a headache of
any intensity (Log Rank, p=0.264). There was also no difference between
the 2 groups with respect to the time of onset of a headache of moderate
or severe intensity (Log Rank, p=0.634).
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